SELLAS Life Sciences Group, Inc. — Director's Dealing 2017

Dec 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2017-12-29

Reporting Person: SCHEINBERG DAVID A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-29	Common Stock	A	9107	—	Acquired	9107	Direct

Footnotes

F1: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.

F2: Represents shares issuable upon vesting of RSUs. 100% of the shares subject to the RSUs will vest on February 27, 2018.